Derek Chalmers, Cara Therapeutics CEO

Cara, Vi­for Phar­ma score speedy FDA nod on itch­ing drug for CKD — shares surge

The FDA has ap­proved Cara Ther­a­peu­tics and Vi­for Phar­ma’s Ko­r­su­va (dife­like­falin), a nov­el kap­pa opi­oid re­cep­tor ag­o­nist in­jec­tion to treat se­vere-to-mod­er­ate pru­ri­tis, or itch­ing, in pa­tients with chron­ic kid­ney dis­ease un­der­go­ing dial­y­sis, the com­pa­nies said Mon­day.

The part­ners ex­pect to launch in Q1, they said in a state­ment, and are cur­rent­ly as­sem­bling a re­im­burse­ment pack­age with the Cen­ters for Medicare and Med­ic­aid Ser­vices for sub­mis­sion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.